Regula Helps Austrian Municipalities Facilitate ID Verification and Processing
10.9.2024 08:00:00 CEST | Business Wire | Press release
Municipal registration offices across Austria have integrated advanced document readers Regula 7024M to automate and secure identity verification processes. This initiative is part of the “Sicheres Meldeamt” (secure registration office) project, launched by the Federal Ministry of Internal Affairs of Austria.
In Austria, the municipal registration office (Meldeamt) plays a crucial role in the administrative process for both citizens and residents. It's where individuals are required to register their place of residence, which is an essential part of living in Austria. However, its role extends beyond mere registration; it facilitates a smooth transition for individuals moving within or to Austria, granting them access to public services and contributing to orderly municipal management.
The need for modernization
Traditionally, the verification of identity documents in Austrian registration offices has been based predominantly on manual work, which requires a certain level of expertise, is time-consuming and prone to errors. Recognizing the need for more efficient and hurdle-free operations, theMinistry of Internal Affairs has launched the “Sicheres Meldeamt” initiative and has offered registration offices a new approach to automate identity document reading and verification.
The solution
To realize the “Sicheres Meldeamt” project across the whole country, cooperation with IT service providers to Austrian registration offices was initiated. Among these providers are Kufgem, Gemdat OÖ, PSC, Comm-Unity EDV, Gemdat NÖ, and others. They have offered to equip registration offices with compact desktop document readers Regula 7024M.
Regula’s devices were chosen because they feature advanced OCR technology tailored for identity documents, MRZ and barcode reading modules, and multiple light sources. It helps Regula 7024M accurately identify various data types, including engraved and embossed text. Additionally, the device comes equipped with an RFID chip reading module to enable the verification of biometric documents. By performing extensive data cross-checks, Regula 7024M helps identify any possible inconsistencies in personal information that may indicate fraud.
First results and future prospects
The pilot projects in cities like Linz, Telfs, and Sankt Pölten have shown significant improvements in the registration processes. With Regula 7024M, documents are processed instantaneously, significantly reducing the manual workload and virtually eliminating human error.
Christoph Heichinger, Ministerial Councillor from the Central Office of the Federal Ministry of Internal Affairs of Austria and one of the project managers of the “Sicheres Meldeamt” project, stated, "The digital enhancement of the registration process allows registration offices to create effective protection mechanisms against the unauthorized use of registration confirmations. This is achieved by using high-quality passport and document readers for verifying documents."
Now, the “Sicheres Meldeamt” project is going to be extended to other registration offices in Austria.
“We are immensely proud to see our document readers streamlining and securing ID processing in Austrian registration offices. Regula 7024M is a powerful tool capable of transforming the daily operations of border controls and immigration services. This initiative sets a new nationwide benchmark for identity verification and we look forward to continuing our support for the ‘Sicheres Meldeamt’ project as it expands across the country,” said Maris Kaminskis, Executive Director at Regula Europe.
To learn more about Regula’s involvement in the “Sicheres Meldeamt” project, please read the success story.
About Regula
Regula is a global developer of forensic devices and identity verification solutions. With our 30+ years of experience in forensic research and the largest library of document templates in the world, we create breakthrough technologies in document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security or speed. Regula was repeatedly named a Representative Vendor in the Gartner® Market Guide for Identity Verification.
Learn more at www.regulaforensics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240909830261/en/
Contacts
Kristina – ks@regulaforensics.com
Kristina – ks@regulaforensics.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom